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Senescence and tumour clearance is triggered by p53
restoration in murine liver carcinomas
Wen Xue1*, Lars Zender1*, Cornelius Miething1, Ross A. Dickins1,2, Eva Hernando3, Valery Krizhanovsky1,
Carlos Cordon-Cardo3 & Scott W. Lowe1,2
Although cancer arises from a combination of mutations in onco-
genes and tumour suppressor genes, the extent to which tumour
suppressor gene loss is required for maintaining established
tumours is poorly understood. p53 is an important tumour sup-
pressor that acts to restrict proliferation in response to DNA
damage or deregulation of mitogenic oncogenes, by leading to
the induction of various cell cycle checkpoints, apoptosis or cel-
lular senescence1,2. Consequently, p53mutations increase cell pro-
liferation and survival, and in some settings promote genomic
instability and resistance to certain chemotherapies3. To deter-
mine the consequences of reactivating the p53 pathway in
tumours, we used RNA interference (RNAi) to conditionally regu-
late endogenous p53 expression in a mosaic mouse model of liver
carcinoma4,5. We show that even brief reactivation of endogenous
p53 in p53-deficient tumours can produce complete tumour
regressions. The primary response to p53 was not apoptosis, but
instead involved the induction of a cellular senescence program
that was associated with differentiation and the upregulation of
inflammatory cytokines. This program, although producing only
cell cycle arrest in vitro, also triggered an innate immune response
that targeted the tumour cells in vivo, thereby contributing to
tumour clearance. Our study indicates that p53 loss can be
required for the maintenance of aggressive carcinomas, and illus-
trates how the cellular senescence program can act together with
the innate immune system to potently limit tumour growth.
p53 mutations are common in human liver cancer6, which is typ-
ically highly aggressive and resistant to non-surgical therapies. To
determine the requirement for p53 loss in the maintenance of such
carcinomas, we used reversible RNAi7 to control p53 in a chimaeric
liver cancer mouse model (Fig. 1a)4,5. Purified embryonic liver pro-
genitor cells (hepatoblasts) were transducedwith retroviruses expres-
sing oncogenic ras (HrasV12), the tetracycline transactivator protein
tTA (‘tet-off’) and a tet-responsive p53 miR30 design short hairpin
RNA (shRNA; Supplementary Fig. 1a)7,8, and seeded into the livers of
athymic nude mice following intrasplenic injection4,5. To facilitate in
vivo imaging, the oncogenic ras retrovirus co-expressed green fluor-
escent protein (GFP) and, in some experiments, hepatoblasts were
also co-transduced with a luciferase reporter.
p53 expression was efficiently suppressed in the absence of
doxycycline (Dox) and rapidly restored following Dox addition
(Supplementary Fig. 1b, c). On transplantation into the livers of
recipient mice, hepatoblast populations co-expressing Ras and the
conditional p53 shRNA rapidly produced invasive hepatocarcinomas
in the absence of Dox (Fig. 1b), whereas cells expressing each vector
alone did not (data not shown). These tumours were GFP-positive
and, if expressing luciferase, could be visualized externally by bio-
luminescence imaging (Fig. 1b).
Animals with advanced tumours were treated with Dox to re-
establish p53 expression (Fig. 1b). Shortly after Dox administration,
the p53 microRNA (miRNA) was shut off and p53 expression
increased (Supplementary Fig. 1). Although tumours in untreated
mice rapidly progressed, those in Dox-treated animals began to
involute and became nearly undetectable within 12 days (Fig. 1b).
Similar results were observed in a subcutaneous setting, where
tumours could be accurately monitored using calliper measurements
(Fig. 1c, left panel). Importantly, ras-induced liver carcinomas pro-
duced using a constitutive p53 shRNA grew similarly irrespective of
Dox treatment (Fig. 1c, right), indicating that tumour regression was
not due toDox toxicity. Such regressions also occurred when p53was
reactivated in tumours co-expressing a constitutively activated Akt
or an endogenous oncogenic K-ras allele and the conditional p53
shRNA (W.X., L.Z. and S.W.L., unpublished data).
To determine whether transient p53 reactivation could also cause
tumour regression, we treated transformed cells in culture or
tumour-bearing mice with Dox for 4 days and then removed the
drug. Immunoblotting revealed that p53 could be transiently
induced following Dox addition and withdrawal (Fig. 1d). In cul-
tured cells, even two days of Dox treatment reduced colony forma-
tion to levels observed following continuous Dox treatment
(Supplementary Fig. 2a). Furthermore, both in situ and subcutan-
eous liver carcinomas showed complete regressions after only four
days of Dox treatment (Fig. 1e; Supplementary Fig. 2b). Thus, p53
can induce tumour involution through a process that, once activated,
seems irreversible. These observations are analogous to results seen
in murine tumours conditionally expressing various oncogenes,
where silencing of the initiating oncogene often causes tumour
regression9,10.
The rapid involution of hepatocarcinomas re-expressing p53 is
consistent with p53’s well-characterized ability to promote apopto-
sis. We therefore examined apoptosis and proliferation in tumours
before and after p53 restoration (Fig. 2a, b). Surprisingly, we
observed few cells that were TUNEL-positive or contained activated
caspase 3 following p53 reactivation, suggesting that the primary
response to p53 was not apoptosis. Similarly, substantial necrosis
was not observed in the regressing tumours. Instead, these tumours
showed amarked decrease in proliferation (Ki67) that was associated
with signs of cellular differentiation (Supplementary Fig. 3).
p53 can also promote cellular senescence, an apparently irrevers-
ible form of cell cycle arrest that is a potent barrier to tumori-
genesis11–14 and can be triggered by hyperactive Ras or PI3K
signalling12,15. Interestingly, hepatocarcinomas expressing either
oncogenic ras or Akt showed clear signs of senescence following p53
reactivation in vivo (Fig. 3a–c; data not shown for Akt), including the
accumulation of senescence-associated-b-galactosidase (SA-b-Gal)
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activity (Fig. 3a, b) and the senescence markers p16INK4a, DcR2 and
p15INK4b (Fig. 3c)13,15. SA-b-gal activity was also observed in tumours
following brief Dox treatment (Fig. 3b), indicating that a pulse of p53
activity was sufficient to trigger senescence in vivo.
That p53 activation induces both cellular senescence and tumour
involution is surprising given that senescence is a cytostatic program.
Indeed, transformed cells accumulated SA-b-gal activity but sub-
sequently remained arrested following p53 reactivation in vitro
(Fig. 3d–f), suggesting that tumour regression involves non-cell-
autonomous processes. Microscopic examination of tumours har-
vested at different times following p53 reactivation revealed a
progressive inflammatory reaction involving polymorphonuclear
leukocytes, initially developing in peri-tumoral regions and ulti-
mately spreading throughout the tumour (Fig. 4a–f). We also
observed an intense perivascular infiltration in regressing tumours,
leading eventually to an overt vasculitis characterized by sclerosed
vessels, hemorraghia and erythrophagocytosis (Supplementary Fig.
7). Morphological, immunofluorescence and flow cytometric ana-
lyses identified the infiltrating leukocytes as neutrophils, macro-
phages and natural killer cells (Supplementary Figures 4–6). These
histopathological features support a model of sequential events,
initiated by p53 reactivation in the tumour, activation of a dramatic
inflammatory response, followed by destruction of tumour cells and
neo-vasculature.
Senescent cells often acquire a gene expression signature that
includes the upregulation of inflammatory cytokines and other im-
mune modulators16,17. Accordingly, inflammatory cytokines known
to attract macrophages (Csf1 and Mcp1), neutrophils (Cxcl1) and
natural killer cells (Il15) were upregulated in liver tumours shortly
following p53 reactivation (Fig. 4g). These genes were also induced
by p53 in cultured hepatoma cells, demonstrating that they are
expressed in tumour cells, not merely the infiltrating leukocytes
(Fig. 4g). Moreover, several adhesion molecules including Icam1
(ref. 18) and Vcam1 were induced following p53 reactivation
(Fig. 4g, and data not shown), indicating one way in which senescent
cells could facilitate immune recognition. Finally, transcripts
specific for neutrophils (Ncf2, Ncf4), macrophages (Mgl2, MSR2,
CD68) and natural killer cells (Klrb1, Klrd1) were increased in sen-
escent tumours but not cultured cells. Thus, multiple components
of the innate immune system infiltrate the tumours following p53
reactivation.
To determine whether innate immune cells were required for
tumour clearance, mice bearing subcutaneous hepatocarcinomas
harbouring the conditional p53 shRNAwere treatedwith gadolinium
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Figure 1 | Reactivation of p53 results in liver tumour regression.
a, Embryonic liver progenitor cells were transduced with a tetracycline-
regulatable p53 shRNA (TRE.shp53), tTA andH-rasV12. After onset of liver
tumours, p53 expression could be restored by doxycycline (Dox) treatment.
b, Reactivation of p53 leads to rapid tumour regression. Tumour-bearing
micewere treatedwithDox starting at day 0 and imaged at the indicated time
points (n5 9). c, Subcutaneous tumours derived from ras-transformed liver
progenitor cells with tet-off shRNA (TRE.shp53) or a non-regulatable
shRNA (MLS.shp53) were grown in nude mice. Values represent
mean6 s.d. (n5 4). d, p53 reactivation is reversed by Dox withdrawal.
Protein lysates from liver progenitor cells pulse-treated with Dox for 4 days
were immunoblotted for p53. e, Representative mice (n5 6) as in b were
pulse-treated with Dox for 4 days and imaged at the indicated time.
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chloride (a macrophage toxin)19,20 or neutralizing antibodies to sup-
press neutrophil or natural killer cell function20,21, andmonitored for
tumour regression following Dox treatment. All three treatments
significantly delayed tumour regression following p53 reactivation
(Fig. 4i), thus confirming that components of the innate immune
system were actively involved in tumour clearance, presumably
through a coordinated response. Importantly, each antagonist effi-
ciently and specifically depleted the targeted immune cells from the
spleen or peripheral blood (Supplementary Fig. 8), but did not pre-
vent tumour cell senescence (Fig. 4j). Similarly, almost no tumour
regression was observed following p53 reactivation in tumours
grown in NOD/SCID mice —which have a highly impaired innate
immune system22—even though p53 still induced cytostasis and sen-
escence (Supplementary Fig. 9). Therefore, the delay in tumour clear-
ance cannot be explained by a failure of the immune system to
phagocytose dead or dying cells. Instead, these results indicate that
the induction of cellular senescence and the evoked immune attack
cooperate to promote tumour clearance. Of note, the athymic nude
mice used here lacked functional B and T cells, which typically poten-
tiate, but can also attenuate, inflammatory responses23. However, p53
reactivation in murine sarcomas also can induce senescence and
tumour clearance in a completely immunocompetent setting24.
Our study used regulatable RNAi to demonstrate that p53 loss is
required for maintenance of aggressive hepatocarcinomas. We sus-
pect that tumours harbouring p53 mutations may be hypersensitive
to restoration of p53 signalling because they have oncogenic lesions
or damage signals capable of potently activating p53 (refs 3,25). Still,
the consequences of restoring p53 signalling may depend on tumour
origin or genotype; thus, whereas p53 reactivation induces sen-
escence in liver carcinomas and sarcomas, lymphoid tumours
respond to p53 by undergoing apoptosis24. Tumours may also even-
tually escape their dependence on p53 mutations, but the fact that
brief reactivation can cause complete tumour regressions supports
the potential of transient p53 reactivation therapies26,27, even for
advanced cancers.
Our results also identify a novel mechanism of tumour suppres-
sion involving cooperative interactions between a tumour cell sen-
escence program and the innate immune system. They further
demonstrate that, despite the cytostatic nature of the senescence
program, senescent cells can turn over in vivo. Whether such turn-
over is a general feature of senescence in vivo is not clear14,28, but when
presentmay reinforce the tumour suppressive action of senescence in
pre-malignant settings or in tumours following treatment with sen-
escence- or differentiation-promoting therapies26,29. Conversely, our
results identify a setting in which the innate immune system is pro-
voked to coordinately attack tumour cells, presumably through both
phagocytosis and direct cytotoxic killing, thereby facilitating their
elimination. Although it is established that chronic inflammation
triggered by senescent stromal cells or other factors can promote
tumorigenesis19,30, our study illustrates how innate immune cells—
when targeted against senescent tumour cells—can have anti-tumour
effects as well. Strategies that specifically harness these processes may
represent a promising therapeutic approach.
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Figure 2 | The primary response to p53 reactivation is not apoptosis.
a, Haematoxylin and eosin (H&E) immunohistochemical staining for
apoptotic cells (TUNEL andCaspase 3 staining) and proliferating cells (Ki67
staining) of liver tumours before (p53 off) and after Dox treatment (p53 on).
Tumours showed histopathology of human hepatocellular and
cholangiocellular carcinoma. Inset (P) denotes positive controls (irradiated
thymus, 20Gy (20 Gray)). ‘p53 on’ shows representative tumour on day 6.
Scale bar, 100mm. b, Quantification of a. Values represent mean6 s.d.
(n5 4; **P, 0.002).
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Figure 3 | p53 reactivation induces cellular senescence. a, SA-b-Gal
staining of representative tumour-bearing livers untreated (p53 off) or
treated with Dox (p53 on, day 6) (n5 3). b, SA-b-Gal staining of tumour
sections (n 5 3). Tumours were either untreated (p53 off), constantly
treated with Dox for 8 days (p53 on 8 days) or briefly treated for 4 days and
left untreated for 8 days (p53 on 4 days/off 8 days). Scale bar, 25 mm.
c, Immunoblotting for senescence markers in normal liver or liver tumours
treated with Dox for 0, 4 and 6 days. d, Liver progenitor cells harbouring ras
and tet-off shp53 were cultured in Dox-containing medium for 6 days (p53
on) and stained for SA-b-Gal. Values represent mean6 s.d. (n 5 3;
**P, 0.0001). e, Representative pictures from d. f, Cells as in d were
cultured with (p53 on, red line) or without Dox (p53 off, black line) and cell
numbers were counted. Values represent mean6 s.d. (n5 4).
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METHODS
See Supplementary Methods for detailed experimental methods.
Generation and analysis of liver tumours. Isolation, culture and retroviral
infection of murine hepatoblasts were as described4,5. Doxycycline treatment
(BD Biosciences) and bioluminescence imaging (Xenogen) was performed
according to the manufacturer’s instructions. Histopathological evaluation
was performed by an experienced pathologist (C.C.C.). Immunohisto-
chemistry was performed as described5.
Tumour characterization. Fresh tumour tissue was lysed in Laemmli buffer
using a tissue homogenizer and analysed by immunoblotting by standard pro-
cedures with the indicated antibodies. Detection of SA-b-gal activity was per-
formed as described at pH 5.5 (ref. 7). Sections (10mm) of snap frozen tumour
tissue were fixed with 1% formalin for 1min and stained for 12 h. Tumour-
bearing livers were fixed with 4% formalin overnight and stained for 4 h.
Cultured cells were fixed with 4% formalin for 5min and stained for 10 h.
RNA expression analyses. RNA isolation (Qiagen) and TaqMan reverse tran-
scriptase reaction (Applied Bosystems) were according to the manufacturer’s
instructions. Quantitative PCR (qPCR) reactions (Bio-Rad) for each sample
were done in triplicate. Microarray experiments were performed on Mouse
Genome 430A 2.0 arrays (Affymetrix).
Data analysis. All the statistical analysis was done by Student’s t-test.
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